(Q36135493)

12 August 2017

1 reference

title

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update (English)

1 reference

12 August 2017

1 reference

1 reference

1

0 references

Geoff McCaughan

6

object named as

Geoff McCaughan

1 reference

12 August 2017

Nancy Leung

2

1 reference

12 August 2017

Richard Guan

3

1 reference

12 August 2017

George K K Lau

4

1 reference

12 August 2017

Ismail Merican

5

1 reference

12 August 2017

Edward Gane

7

1 reference

12 August 2017

Jia-Horng Kao

8

1 reference

12 August 2017

Masao Omata

9

1 reference

12 August 2017

Asian-Pacific consensus update working party on chronic hepatitis B

10

1 reference

12 August 2017

1 June 2005

1 reference

12 August 2017

1 reference

12 August 2017

25

1 reference

12 August 2017

3

1 reference

12 August 2017

472-489

1 reference

Asian-Pacific consensus statement on the management of chronic hepatitis B: an update

12 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Varied assembly and RNA editing efficiencies between genotypes I and II hepatitis D virus and their implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Mechanisms of action of interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Hepatitis B e antigen and the risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Hepatitis B viral genotypes: clinical relevance and molecular characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Hepatitis B virus genotypes in the United States: results of a nationwide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Core promoter mutations (A(1762)T and G(1764)A) and viral genotype in chronic hepatitis B and hepatocellular carcinoma in Guangxi, China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Interferon monotherapy in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Drug treatment of pediatric chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Role of steroid priming in the treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Long-term evaluation of recombinant interferon alpha2b in the treatment of patients with hepatitis B e antigen-negative chronic hepatitis B in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Interferon-alpha for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Use of immunomodulatory therapy (other than interferon) for the treatment of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Prevalence of hepatitis C virus infection in patients with antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Clinical trial of lamivudine in children with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Results of lamivudine trials in Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Determinants for sustained HBeAg response to lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Histological outcome during long-term lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Beneficial effects of 'lamivudine pulse' therapy in HBeAg-positive patients with normal ALT*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

S-adenosylmethionine and its metabolite induce apoptosis in HepG2 cells: Role of protein phosphatase 1 and Bcl-x(S).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Role of hepatitis C virus in dual and triple hepatitis virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Changes in serum albumin during treatment of chronic hepatitis B with lamivudine: effects of response and emergence of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Clinical economics review: liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Prophylaxis with anti-HBs immune globulins and nucleoside analogues after liver transplantation for HBV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Hepatitis B genotypes and the response to interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01134.X

10.1111/J.1478-3231.2005.01134.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference